Shanghai's concentration of hospitals, patients and clinicians is emerging as a key driver of its biopharma ambitions, though turning that advantage into sustained innovation will depend on stronger links across research, industry and capital.
Jin Chunlin, director of the Shanghai Health Development Research Center
by LI Kewen
Shanghai is positioning itself as a hub for biopharma innovation, supported by its concentration of clinical resources, relatively mature investment environment and a growing base of innovative drug companies.
At the "Shanghai 2035: Answers for the Future" roundtable's biopharma session, Jin Chunlin, director of the Shanghai Health Development Research Center, said the city's main structural advantage lies in its dense clinical ecosystem. Biopharma innovation, he said, ultimately begins with clinical demand.
Shanghai's network of high-level hospitals, large patient base and active physician participation provide conditions to identify unmet medical needs and support clinical and real-world research. This, in turn, helps shape research priorities and development pathways.
However, Jin noted that clinical resources alone do not automatically translate into innovation capacity. The key is whether these resources can be converted into research questions, technical approaches and viable products. Shanghai has developed relatively strong linkages between hospitals, research institutions and companies, which he said form the basis for this transition.
He added that further progress will depend on strengthening research-oriented hospitals and improving coordination across the innovation chain, allowing clinical insights to feed more directly into original research.
Jin also highlighted the role of long-term capital. Drug development is typically costly, high-risk and time-intensive, requiring sustained investment and clear exit mechanisms. Shanghai's financing environment — supported by the STAR Market, industrial funds and the presence of multinational pharmaceutical companies — provides a degree of support for early-stage projects.
A remaining challenge is whether innovation can be translated into widespread clinical use. The city has introduced policies covering R&D, clinical trials, regulatory approval, application and payment. As growth in the basic medical insurance system becomes more constrained, Jin said commercial health insurance is likely to play a larger role in supporting access to innovative drugs.
Editor's note: "Shanghai 2035: Answers for the Future" is a multimedia series produced by the Shanghai Municipal Government Information Office and Jiemian News. The project explores the city's long-term development across key sectors through documentaries, expert roundtables and interviews. The biopharma chapter examines how Shanghai is developing its drug innovation ecosystem, with a focus on clinical resources, commercialization pathways and global expansion.
